Apr 9, 2013 by Max MacalusoThe Weaknesses in Sanofi's Diabetes FranchiseFrench pharmaceutical company Sanofi is best known for its blockbuster insulin drug Lantus, but can the company maintain its lead in the diabetes market?
Apr 9, 2013 by Max MacalusoThe Most Surprising FDA Decisions of 2013We're only three months into 2013, but has the Food & Drug Administration already made some surprising decisions?
Apr 9, 2013 by Max MacalusoThe Role Medication Plays in Treating ObesityDiet and exercise are just part of the weight-management equation. Sometimes, treatment also involves prescription drugs.
Apr 6, 2013 by Max MacalusoHow Doctors Actually Diagnose ObesityObesity is already a hotly debated public health topic. How are patients actually diagnosed for this disease?
Apr 6, 2013 by Max Macaluso, Brenton Flynn, and Dave WilliamsonHow the "BRAIN Initiative" Can Help Big PharmaA cure for Alzheimer's has been elusive - can the BRAIN project shed light on this disease?
Apr 5, 2013 by Max Macaluso, Brenton Flynn, and Dave WilliamsonThis Week in Health CareThe Motley Fool Health-Care Show for Friday April 5th.
Apr 4, 2013 by Max MacalusoHealth Care's Elite Eight Stocks: Johnson & Johnson vs. NovartisWho will prevail in this head-to-head match-up?
Apr 3, 2013 by Max MacalusoShould Novartis Investors Worry About This Supreme Court Ruling?How will this ruling on Glivec's patent affect Novartis' revenue this year?
Apr 3, 2013 by Max MacalusoShould Merck Investors Worry About This Supreme Court Decision?Can the Supreme Court of India's ruling on Novartis' Gleevec also effect Merck?
Mar 31, 2013 by Max Macaluso and Brenton FlynnMarket Madness Showdown: AstraZeneca vs. MerckWho will win this round?
Mar 30, 2013 by Max Macaluso and Dave WilliamsonMarket Madness Showdown: Sanofi vs. Eli LillyYou might be more interested in March Madness, but if you're a long-term investor, the first round of Market Madness will keep you on the edge of your seat.
Mar 30, 2013 by Max Macaluso and Dave WilliamsonMarket Madness Showdown: AbbVie vs. GlaxoSmithKlineYou might be more interested in March Madness, but if you're a long-term investor, the first round of Market Madness will keep you on the edge of your seat.
Mar 29, 2013 by Max Macaluso and Brenton FlynnMarket Madness Showdown: Abbott vs. Novo NordiskYou might be more interested in March Madness -- but if you're a long-term investor, the first round of Market Madness will keep you on the edge of your seat.
Mar 29, 2013 by Max Macaluso, Brenton Flynn, and Dave WilliamsonIs IBM's Watson Really a Big Deal?IBM's supercomputer Watson has stolen the headlines lately, but this isn't the first time that computing has been applied to medicine.
Mar 28, 2013 by Max Macaluso, Brenton Flynn, and Dave WilliamsonWill This Upcoming FDA Decision Give Allergan a Headache?The FDA is set to decide whether or not Allergan's migraine drug Levadex gets the green light in the coming weeks.
Mar 28, 2013 by Max Macaluso, Brenton Flynn, and Dave WilliamsonWas Obagi Medical the Right Acquisition for Valeant?Obagi Medical Products shareholders won big last week -- but what should Valeant investors think of this buyout?
Mar 28, 2013 by Max Macaluso, Brenton Flynn, and Dave WilliamsonJohnson & Johnson Waits for FDA Ruling on new Diabetes DrugStay tuned investors: The FDA's decision on Johnson & Johnson's type 2 diabetes drug Invokana should arrive soon.
Mar 26, 2013 by Max MacalusoIs This Obesity-Drug Maker in Trouble?VIVUS announced a financing deal that could be worth $110 million. What does this mean for investors?
Mar 25, 2013 by Max MacalusoFDA Deliberates on an Emerging Type 2 Diabetes Drug ClassSGLT-2 inhibitors could become a new option for Type 2 diabetics -- but the FDA has to approve them first..
